Flashcards · Module 34
🩸 Peripheral Vascular & Thromboembolic Disease
4 of 4 cards published · read by the site’s author on 21 November 2026
Peripheral Artery Disease (PAD) & The Ankle-Brachial Index (ABI): The stiff artery trap!
Needs clinical review
How the ABI Works:
\text{ABI} = \frac{\text{Highest Systolic BP at Ankle (DP or PT)}}{\text{Highest Systolic BP in either Arm (Brachial)}}
Diagnostic Tiers:
Normal: 1.00 to 1.40
Borderline: 0.91 to 0.99
Abnormal (PAD): ≤ 0.90 (high specificity ~89%, moderate sensitivity ~65% for ≥50% arterial stenosis)
Severe Ischemia: < 0.40 (critical limb-threatening ischemia)
The Huge Geriatric Trap: ABI > 1.40 (Non-Compressible Arteries)
In older adults with diabetes or end-stage renal disease, Mönckeberg medial calcific sclerosis turns the tibial arteries into rigid, calcified lead pipes!
The blood pressure cuff cannot compress the stone-hard artery, resulting in a falsely elevated ABI > 1.40!
🚨 The Mistake: Believing an ABI of 1.45 means "great circulation."
✅ The Correct Test: Order a Toe-Brachial Index (TBI): it detects PAD when the ankle arteries are incompressible; TBI < 0.70 is the guideline threshold.
Sources checked (7) · 18 November 2026
- Prevalence of Peripheral Artery Disease by Ankle-Brachial and Toe-Brachial Indices and Factors Associated with Toe-Brachial Index-Defined Disease in Maintenance Hemodialysis Patients (2026)
- Ankle Brachial Index (2026)
- Vascular Aging and Bladder Health: Associations Between Peripheral Arterial Disease and Lower Urinary Tract Symptoms in Mid-Life Women from CARDIA-PLUS (2026)
- Diagnostic Accuracy of Ankle-Brachial Index in Patients With Peripheral Arterial Disease: A Meta-analysis (2025)
- Pre-Operative Ankle Brachial Index in Assessing Major Amputation Level and Outcomes in Patients With Peripheral Artery Disease (2026)
- Monckeberg's Medial Sclerosis in Athletes: Report of Two Cases and Possible Pathophysiological Mechanisms (2026)
- Clinical Characteristics and Angioplasty Outcomes in Lower Extremity Artery Disease Patients with Normal Ankle-Brachial Index: A Clinical Conundrum (2025)
Note: Incompressible ankle arteries from medial arterial calcification in diabetes or hemodialysis can yield falsely normal or elevated ABI values and underestimate PAD. (Prevalence of Peripheral Artery Disease by Ankle-Brachial and Toe-Brachial Indices and Factors Associated with Toe-Brachial Index-Defined Disease in Maintenance Hemodialysis Patients (2026))
Note: Toe-brachial index measurement detects PAD in patients with incompressible ankle arteries due to medial arterial calcification, most frequently associated with diabetes. (Screening for Peripheral Artery Disease Using an Automated Four-Limb Blood Pressure Monitor Equipped with Toe-Brachial Index Measurement (2023))
Abdominal Aortic Aneurysm (AAA) Screening & Rupture Risk
Needs clinical review
The Silent Killer:
Most AAAs cause no symptoms until they rupture, and the risk of death with rupture is as high as 81%!
The USPSTF Screening Recommendation:
One-time screening ultrasound for abdominal aortic aneurysm in:
Men aged 65 to 75 who have EVER smoked (≥100 lifetime cigarettes).
Size Cutoffs and Interventions:
| Aneurysm Diameter | Rupture Risk | Management Protocol |
|---|---|---|
| < 4.0 cm | Low | Surveillance ultrasound every 3 years (3.0–3.9 cm) |
| 4.0 to 5.4 cm | Moderate | Surveillance ultrasound every 6 to 12 months |
| ≥ 5.5 cm (or rapid expansion >0.5 cm in 6 months) | HIGH: about 9–10%/year at 5.5–6.9 cm, 32.5% at ≥7 cm | 🚨 Elective Repair (EVAR or open surgery) |
| Women cutoff | Lower threshold | ≥ 5.0 cm (women rupture at smaller diameters!) |
EVAR in Frail Elders:
Endovascular Aneurysm Repair (EVAR) places a stent-graft via the femoral arteries, avoiding cross-clamping and laparotomy, with much lower 30-day perioperative mortality.
Sources checked (8) · 18 November 2026
- Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement (2019)
- Arterial Atherosclerosis: Vascular Surgery Interventions (2022)
- Surveillance outcomes of small abdominal aortic aneurysms identified from a large screening program (2016)
- Peripheral arterial disease and abdominal aortic aneurysm in elderly people (2011)
- Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair (2002)
- Type II endoleaks: diagnosis and treatment algorithm (2018)
- Optimizing predictive performance without sacrificing explainability: Comparing logistic regression and ensemble decision trees for abdominal aortic aneurysm repair outcomes (2026)
- [Abdominal aortic aneurysms: diagnosis, risk stratification and treatment strategies] (2026)
Note: USPSTF gives a Grade C recommendation to selectively offer screening to men aged 65 to 75 years who have never smoked, Grade D against routine screening in women who have never smoked and have no family history of AAA, and an I statement for women aged 65 to 75 years who have ever smoked or have a family history. (Screening for Abdominal Aortic Aneurysm: US Preventive Services Task Force Recommendation Statement (2019))
Note: In EVAR-1, EVAR achieved lower 30-day mortality (1.8% vs 4.3% for open repair) with comparable long-term outcomes up to 15 years, at the cost of a 15-20% reintervention burden and lifelong imaging surveillance. ([Abdominal aortic aneurysms: diagnosis, risk stratification and treatment strategies] (2026))
Deep Vein Thrombosis & Pulmonary Embolism: The Age-Adjusted D-Dimer
Needs clinical review
The Problem with D-Dimer in Elders:
In young patients, a standard D-dimer cutoff of 500 μg/L safely rules out DVT and PE. But in healthy older adults, baseline D-dimer levels naturally rise due to age-related endothelial activation and inflammaging.
Among patients aged ≥75 with suspected PE, the 500 µg/L cutoff ruled out PE in only 6.4%!
Result: with a 500 µg/L cutoff, most older patients with suspected PE go on to CT pulmonary angiography.
The Solution: Age-Adjusted D-Dimer Cutoff (for Age > 50)
\text{Age-Adjusted D-Dimer Cutoff} = \mathbf{\text{Age (years)}} \times 10 \ μ\text{g/L}
Examples:
At age 70: Cutoff is 700 μg/L
At age 85: Cutoff is 850 μg/L
Clinical Utility (The ADJUST-PE Trial):
In patients with non-high pretest clinical probability, the age-adjusted formula increased PE exclusion from 28.2% to 39.8% overall—and from 6.4% to 29.7% (+23.3%) in patients aged ≥75 years—with a 3-month VTE failure rate of only 0.3% (1 of 331 patients).
Age × 10 μg/L) to safely rule out PE without unnecessary CT scans.DOAC Dosing in Extreme Age, Low Weight & CKD: The Apixaban "ABC Rule"
Needs clinical review
Direct Oral Anticoagulants (DOACs) in Frail Elders:
DOACs (Apixaban, Rivaroxaban, Dabigatran, Edoxaban) cause about half the intracranial hemorrhage of warfarin (RR 0.48). But dosing must be adjusted carefully!
The Apixaban (Eliquis) "ABC Rule" for Non-Valvular A-Fib:
Standard dose is 5 mg PO BID.
Reduce the dose to 2.5 mg PO BID IF the patient meets AT LEAST 2 of the following 3 criteria (A-B-C):
🎂 A — Age: Age ≥ 80 years
⚖️ B — Body Weight: Weight ≤ 60 kg (132 lbs)
🫘 C — Creatinine: Serum Creatinine ≥ 1.5 mg/dL (133 μmol/L)
The Board Trap:
If an 82-year-old weighs 55 kg but her creatinine is 0.9 mg/dL:
Does she meet 2 criteria? YES! (Age ≥80 AND Weight ≤60 kg).
Dose = 2.5 mg BID!
If an 85-year-old weighs 75 kg with Cr 1.1 mg/dL, she meets only ONE criterion (Age ≥80) → keep standard dose 5 mg BID!
Sources checked (5) · 18 November 2026
- DailyMed - ELIQUIS- apixaban tablet, film coated
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2014)
- Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial (2020)
- Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results (2025)
- Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From AUGUSTUS (2025)
Note: In the same meta-analysis of 71,683 patients, DOACs significantly reduced intracranial hemorrhage and all-cause mortality compared with warfarin, but significantly increased gastrointestinal bleeding. (Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2014))
Note: The dose-reduction rule applies to nonvalvular atrial fibrillation; acute DVT/PE treatment is 10 mg twice daily for the first 7 days followed by 5 mg twice daily. (DailyMed - ELIQUIS- apixaban tablet, film coated)